9 completed, 4 terminated, 2 active not recruiting, 2 withdrawn. 13 Phase 1, 7 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 7, Terminated 4, Unknown 1, Withdrawn 1 |
| Phase 2 | 7 | Active not recruiting 2, Terminated 2, Completed 1, Unknown 1, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow urelumab: new trials by email Literature Review of urelumab trials Research Report on urelumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors Urelumab + Nivolumab - Neoplasms | Phase 1 / Phase 2 | Unknown | Clinica Universidad de Navarra, Universidad de Navarra | 32 | 2019-01-30 | 2019-01-03 |
| Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer Nivolumab, Cabiralizumab, Urelumab - Cancer | Phase 1 | Completed | University of Chicago | 60 | 2018-03-15 | 2023-02-16 |
| Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder Nivolumab in combination with Urelumab, Nivolumab monotherapy - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 15 | 2017-05-16 | 2026-04-06 |
| Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Pharmacological Study - Glioblastoma, Gliosarcoma | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 63 | 2016-08-24 | 2023-10-06 |
| Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas Cyclophosphamide, GVAX pancreatic cancer, Nivolumab - Pancreatic Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 76 | 2016-03-28 | 2026-10-13 |
| Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma Nivolumab, Surgery to Remove Tumor for Growth of TIL, CD137 - Melanoma (Skin), Skin Cancer | Early Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 11 | 2016-03-08 | 2025-08-19 |
| Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors Urelumab, Nivolumab - Malignant Tumors | Phase 1 | Completed | Bristol-Myers Squibb | 18 | 2015-11-06 | 2020-05-18 |
| Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients Rituximab, Urelumab - Leukemia | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2015-07-01 | 2016-12-06 | |
| A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma Elotuzumab, Lirilumab, Urelumab - Multiple Myeloma | Phase 1 | Completed | Bristol-Myers Squibb | 44 | 2014-12-09 | 2017-11-01 |
| An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Urelumab, Nivolumab - Advanced Solid Tumors, Advanced B-cell NHL | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 232 | 2014-09-29 | 2020-10-05 |
| Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer Urelumab, Cetuximab - Colorectal Cancer, Head and Neck Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 66 | 2014-04-01 | 2017-04-19 |
| Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Urelumab, Rituximab - B-Cell Malignancies | Phase 1 | Completed | Bristol-Myers Squibb | 47 | 2013-03-01 | 2017-03-31 |
| Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Urelumab (BMS-663513) - Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma | Phase 1 | Completed | Bristol-Myers Squibb | 124 | 2012-02-01 | 2017-04-19 |
| Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma AntiCD137, Ipilimumab - Melanoma | Phase 1 | Withdrawn | Bristol-Myers Squibb | 2010-11-01 | 2011-11-21 | |
| Phase II, 2nd Line Melanoma - RAND Monotherapy Anti-CD137 (4-1BB) (BMS-663513) - Melanoma | Phase 2 | Completed | Bristol-Myers Squibb | 158 | 2008-03-01 | 2015-10-12 |
| A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC) BMS-663513 - Non Small Cell Lung Cancer | Phase 1 | Terminated | Bristol-Myers Squibb | 35 | 2008-01-01 | 2009-09-04 |
| A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies BMS-663513 - Advanced Solid Malignancies | Phase 1 | Terminated | Bristol-Myers Squibb | 45 | 2007-09-01 | 2009-09-04 |
| Study of BMS-663513 in Patients With Advanced Cancer BMS-663513 - Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 115 | 2005-12-01 | 2015-10-12 |
Neoplasms (4) · Melanoma (3) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Gliosarcoma (1) · Head and Neck Neoplasms (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Multiple Myeloma (1) · Pancreatic Neoplasms (1) · Recurrence (1)
Bristol-Myers Squibb (11) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Clinica Universidad de Navarra, Universidad de Navarra (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · University of Chicago (1)
United States (15) · France (4) · Spain (4) · Canada (3) · Germany (3) · Denmark (1) · Italy (1) · Japan (1)
Amod Sarnaik, M.D. (1) · Ana De Jesus-Acosta, MD (1) · Jason Luke, MD (1) · Micheal Lim, MD (1) · Nitin Jain, MBBS (1) · Noah Hahn, MD (1)
PMID 38458639, PMID 37339979, PMID 41543348, PMID 42432293
2014 (1), R01CA197296 (1), UM1CA137443 (1)